



ASX Announcement

15 March 2018

Creso Pharma enters the sports and osteoarthritis market with innovative CBD-based oral nutraceuticals and functional cosmetics

Highlights:

- **Creso Pharma enters the sports and osteoarthritis market with innovative CBD-based oral nutraceuticals and functional cosmetics addressing the need for organic and efficient relief from muscle and joint pain**
- **Creso Pharma has partnered with the largest independent Swiss manufacturing group FRIKE Technologies to produce a range of innovative proprietary CBD-based functional cosmetics under the cannaDOL® brand**
- **The cannaDOL® topical product range is based on a unique and proprietary blend of CBD and essential oils clinically studied for supporting the reduction of inflammation and muscle pain**
- **The cannaDOL® oral formulation will be a food supplement in a proprietary delivery technology with increased absorption and bioavailability combining CBD with vitamins and minerals supporting collagen synthesis, reducing fatigue and stimulating the metabolism**

Creso Pharma Limited (ASX: CPH), “Creso” or the “Company” will introduce the **cannaDOL®** product range with an oral Cannabidiol-(CBD)-based nutraceutical and first-in-class CBD-based functional cosmetics across Europe to alleviate joint and muscle pain.

cannaDOL® addresses the need for organic and efficient support for the management of pain associated with sports injuries and age-related symptoms such as stiffness and arthritis.

The **cannaDOL®** functional cosmetics product range follows a dual action application concept of cooling and heating formulated to activate the metabolism and promote healing of injuries.

The functional topical cannaDOL® will be provided in two different strengths and will be registered as Cosmetics in the European Union. The cooling effect is generated by menthol whilst the proprietary combination of essential oils heat the targeted area to open up capillaries to penetrate deep into the tissue and stimulate blood circulation in the affected area to accelerate the healing process. The unique dual modes of action are an effective therapy for muscles and joints, providing fast and noticeable relief for cramped and tense muscles.

The **cannaDOL®** oral is a CBD-based food supplement in a proprietary delivery technology with high bioavailability and absorption. The combined CBD, vitamins and minerals formula in the food supplement aims to enhance collagen synthesis, fight fatigue and tiredness and stimulate the metabolism.

cannaDOL® is aimed at people suffering from sports-related muscle injuries, arthritis and osteoarthritis.

The market of analgesics oral and topical make up over 10-20% of that portion of the over-the-counter (OTC) market. The European market has a size of approximately €3.5 billion at public price levels. Analgesics sales volume in Switzerland and UK in 2016 was € 203 Mio, UK € 603mio (Swiss market is high due to price levels).

The market is dominated by NSAID's oral and topicals, with significant unmet needs and potential for growth as sports and osteoarthritis customers are looking for new organic natural treatment alternatives.

Said Dr. Miri Halperin Wernli, Creso Pharma CEO and co-founder: "We are delighted to be partnering with FRIKE Technologies which has an excellent reputation for manufacturing to the highest quality standards for a range of leading global brands across the pharmaceutical, cosmetic and chemical sectors. Given FRIKE's significant expertise in proprietary, innovative Swiss-made formulations we believe they are the perfect partner.

"People's perceptions of cannabis consumption have changed. Cannabis is no longer something to get high on. In the scientific community, CBD advocacy is on the rise, and evidence of its effectiveness across various health issues is growing. As cannabis legalization spreads around the globe, a unique market, based on the health appeals of CBD, is emerging.

"With our innovative CBD-based oral nutraceuticals and functional cosmetics for muscle and joint pain relief in sports and for the aging population, Creso will continue to build our leading position in the global cannabis industry."

Dr. Gian Trepp, Creso Pharma Marketing and Commercial Director said: "Our innovative first in class CBD based oral nutraceuticals and dual action functional cosmetics for muscle and joint pain relief offer additional benefits for sports people and for the ageing population and represent a breaking ground alternative."

The cannaDOL® product range is planned to be launched with commercial partners in the first half 2019.

-ENDS-

Investor Enquiries:

Daniel Solomons
Everblu Capital
P: +61 2 8249 0000
E: info@everblucapital.com

Media Enquiries:

Chris Grundy
Creso Pharma Limited
M: +61 427 306 800
E: chris.grundy@cresopharma.com

About Creso Pharma**www.cresopharma.com**

Creso Pharma brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis- and hemp-derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. Creso Pharma Switzerland develops, produces and markets worldwide cannabis and hemp- derived therapeutics, nutraceuticals and life style products for humans and complementary feed products for animals.

About FRIKE Technologies**<http://www.frike-group.com/en/>**

FRIKE Technologies is a full service contract manufacturer, offering a wide range of production solutions: Development and management of formulas, procurement of raw materials and packaging, bulk production, filling and assembly, warehousing and delivery, outsourcing solutions for productions and machinery. All processes are ISO9001 certified, and the cosmetics division is fully GMP standards certified with ISO22716, IFS HPC, and NaTrue (for natural cosmetics).